Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

    ... , peripheral blood, or both) by World Health Organization (WHO) classification with an intermediate 2 (INT-2) or high-risk score (ie, ≥ 1.5) ...

    Clinical Trial last updated 04/29/2016 - 1:36pm.

  2. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... as: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC < 0.8, PRBC or platelets ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  3. Lower-Risk MDS: Diagnosis and Treatment Options

    ... as less than 5%, 5 to 10%, and 10 to 20%. In the current classification, which is the World Health Organization (WHO) classification, 20% blasts or greater establishes a diagnosis of acute ...

    Interview last updated 05/18/2012 - 1:28pm.

  4. Treating Higher-Risk Myelodysplastic Syndromes

    ... referred to as IPSS, and the World Health Organization (WHO) Prognostic Scoring System, which is known as WPSS. IPSS takes into account ... cytogenetic (chromosomal) abnormalities. The newer WPSS classification system takes into account chromosomal abnormalities like IPSS, ...

    Interview last updated 05/18/2012 - 1:55pm.

  5. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... interesting? There is some evolution in the classification systems used for MDS. For years, we have used the ... that took the IPSS-R and applied it specifically to patients who were on azacitidine (Vidaza®). This is important because both the ...

    Interview last updated 02/07/2013 - 1:28pm.

  6. Research Retrospective for AA&MDSIF 30th Anniversary - Dr. Mikkael Sekeres

    ... Up to that point, there had only been a few hundred patients who had been reported, and it was not until database studies began and the US ... four or five subtypes, or even 10 subtypes (depending on the classification system used), but MDS really represents hundred of subtypes. ...

    Interview last updated 05/08/2013 - 2:51pm.

  7. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... there was a higher UCK 1 mRNA expression in those patients who responded to azacitidine, as compared to those patients who did not.  They ... type of treatment selected depend on the risk category or classification of the MDS? We know that for patients who fail treatment ...

    Interview last updated 06/17/2014 - 9:15am.